Creating EU-CTR compliant and patient-friendly lay language summaries (LLS)

Return to Insights Center

Related Insights

Blog

Breaking through complex regulations and science speak – thinking “patients first” in lay language summary development

Jun 22, 2021

Playbook

Streamlining success: How integrated evidence planning transforms asset development

Feb 27, 2025

Webinar

Accelerating delivery of radiopharmaceutical trials

Oct 3, 2025

Blog

Assessing the need for comparative clinical trials in biosimilar development programs

Sep 21, 2023

Playbook

Mitigating risk, protecting potential: Practical strategies that position cell and gene therapy development for success

Mar 28, 2023

Report

New Medicines, Novel Insights: Advancing rare disease drug development

May 22, 2023

Report

New Medicines, Novel Insights: Accelerating development of cell and gene therapies

May 22, 2023

Webinar

Assessing appropriate use of ECAs in clinical trials

May 28, 2023

Blog

Celebrating 40 Years of Rare Disease Progress: WODC Highlights

Jun 6, 2023

Blog

Population variability: important considerations in vaccine development

Jun 14, 2023

Whitepaper

How to prepare for Policy 0070: Challenges and opportunities for clinical data publication in the EU

Jun 28, 2023

Article

The technologies that are reshaping biotherapeutics manufacturing, an EU perspective

Jul 6, 2023

Related Insights

Blog

Breaking through complex regulations and science speak – thinking “patients first” in lay language summary development

Jun 22, 2021

Playbook

Streamlining success: How integrated evidence planning transforms asset development

Feb 27, 2025

Webinar

Accelerating delivery of radiopharmaceutical trials

Oct 3, 2025

Blog

Assessing the need for comparative clinical trials in biosimilar development programs

Sep 21, 2023

Playbook

Mitigating risk, protecting potential: Practical strategies that position cell and gene therapy development for success

Mar 28, 2023

Report

New Medicines, Novel Insights: Advancing rare disease drug development

May 22, 2023

Show more